Segment and Geographic Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended												12 Months Ended
	Dec. 31, 2014		Sep. 30, 2014	Jun. 30, 2014		Mar. 31, 2014	Dec. 31, 2013		Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013		Dec. 31, 2014 segment	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segment													1
Net revenue	$ 190,998	[1],[2]	$ 172,401	$ 183,774	[1]	$ 177,235	$ 185,003	[3]	$ 174,282	$ 172,826	$ 155,753	[4]	$ 724,408	$ 687,864	$ 558,588
Long-lived assets	1,227,284						1,148,267						1,227,284	1,148,267
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue													687,830	629,459	512,044
Percentage of revenue by geographic segments													95.00%	91.50%	91.70%
Long-lived assets	1,218,370						1,139,210						1,218,370	1,139,210
Percentage of long-lived assets by geographic segments	99.30%						99.20%						99.30%	99.20%
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue													32,859	50,419	38,517
Percentage of revenue by geographic segments													4.50%	7.30%	6.90%
Long-lived assets	8,899						9,035						8,899	9,035
Percentage of long-lived assets by geographic segments	0.70%						0.80%						0.70%	0.80%
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue													3,719	7,986	8,027
Percentage of revenue by geographic segments													0.50%	1.20%	1.40%
Long-lived assets	$ 15						$ 22						$ 15	$ 22
Percentage of long-lived assets by geographic segments	0.00%						0.00%						0.00%	0.00%

[1] Net loss for the second and fourth quarters of 2014 includes impairment charges on product licenses in the amount of $15.1 million and $6.4 million, respectively to cost of sales, as a result of reductions in estimated future cash flows expected to be generated by the acute care generic products as determined by an updated discounted cash flow analysis (Level 3).

[2] In December 2014, the Company entered into a settlement and amendment to the merger agreement with Incline Therapeutics, Inc., which resulted in revisions to certain milestone triggers, a reduction in total milestone payments and the release of the escrow funds to the Company. As a result, net loss for the fourth quarter of 2014 includes $25.7 million in one-time income in connection with the settlement with the former equityholders of Incline related to the representations and warranties included in the merger agreement.

[3] Net income for the fourth quarter of 2013 includes a $10.9 million increase related to the progression in development work for IONSYS related to the Company’s Incline acquisition and a tax benefit of $13.6 million from reducing the Company’s deferred tax liabilities associated with the Incline acquisition.

[4] Net loss for the first quarter of 2013 includes licensing costs of $25.0 million for a transaction with Alnylam on the PCSK9 RNAi hypercholesterolemia program.